文献速递角膜与眼表疾病

MK2抑制剂对实验性小鼠干眼的治疗作用

Therapeutic Effect of MK2 Inhibitor on Experimental Murine Dry Eye.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

该研究在小鼠干燥应激模型中局部应用MK2抑制剂(MK2i)或溶媒滴眼液,发现MK2i可增加泪液分泌、减少杯状细胞丢失、改善角膜屏障功能,并抑制角膜上皮MMP-3和MMP-9表达及眼表细胞凋亡,同时减少CD4+ T细胞浸润并调节Th细胞因子产生。结论认为局部MK2抑制通过抑制细胞凋亡和CD4+ T细胞介导的炎症有效减轻干眼眼表损伤。

要点

  • 局部MK2抑制剂增加干燥应激小鼠泪液分泌并减少杯状细胞丢失。
  • MK2抑制剂改善角膜屏障功能并降低角膜上皮MMP-3和MMP-9表达。
  • MK2抑制剂减少眼表细胞凋亡及CD4+ T细胞浸润,下调IFN-γ和IL-17A、上调IL-13。

核心结论

  • 局部MK2抑制通过抑制细胞凋亡和CD4+ T细胞介导的炎症,有效减轻干眼小鼠眼表损伤。

研究设计与样本

  • 小鼠干燥应激模型,局部应用MK2抑制剂或溶媒滴眼液进行干预。
  • 采用Western blot检测结膜总MK2和磷酸化MK2,酚红棉线试验测泪液分泌,Oregon green dextran染色评估角膜上皮屏障功能。
  • PAS染色定量结膜杯状细胞,免疫荧光和定量RT-PCR评估角膜上皮MMP-3和MMP-9表达。
  • TUNEL及活化caspase-3和caspase-8免疫荧光评估眼表凋亡,CD4+ T细胞浸润及Th细胞因子(IFN-γ、IL-13、IL-17A)评估炎症。

主要发现

  • 干燥应激促进结膜MK2活化。
  • 与溶媒对照组相比,MK2i处理小鼠泪液分泌增加、杯状细胞丢失减少、角膜屏障功能改善。
  • 局部MK2抑制降低干燥应激下角膜上皮MMP-3和MMP-9表达,并抑制眼表细胞凋亡。
  • 局部MK2抑制减少CD4+ T细胞浸润,结膜IFN-γ和IL-17A产生减少、IL-13产生增加。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the role of mitogen-activated protein kinase-activated protein kinase-2 (MK2) in ocular surface damage of dry eye. METHODS: MK2 inhibition was performed in mice subjected to desiccating stress (DS) by topical application of MK2 inhibitor (MK2i) or vehicle eye drops. The total and phosphorylated MK2 in conjunctiva were detected by Western blot. The phenol red cotton test was used to measure tear production, and Oregon green dextran staining was performed to assess corneal epithelial barrier function. PAS staining was used to quantify conjunctival goblet cells. Immunofluorescent staining and quantitative RT-PCR were used to assess the expression of matrix metalloproteinase (MMP)-3 and -9 in corneal epithelium. Apoptosis in ocular surface was assessed by TUNEL and immunofluorescent staining for activated caspase-3 and -8. Inflammation was evaluated by CD4+ T-cell infiltration and production of T helper (Th) cytokines, including IFN-γ, IL-13, and IL-17A in conjunctiva. RESULTS: DS promoted MK2 activation in conjunctiva. Compared with vehicle control mice, MK2i-treated mice showed increased tear production, decreased goblet cell loss, and improved corneal barrier function. Topical MK2 inhibition decreased the expression of MMP-3 and -9 in corneal epithelium, and suppressed cell apoptosis in ocular surface under DS. Topical MK2 inhibition decreased CD4+ T-cell infiltration, with decreased production of IFN-γ and IL-17A and increased production of IL-13 in conjunctiva. CONCLUSIONS: Topical MK2 inhibition effectively alleviated ocular surface damage via suppressing cell apoptosis and CD4+ T-cell-mediated inflammation in ocular surface of dry eye.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wu Y, Bu J, Yang Y, et al. Therapeutic Effect of MK2 Inhibitor on Experimental Murine Dry Eye. Invest Ophthalmol Vis Sci. 2017. PMID: 28973340. doi:10.1167/iovs.17-22240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。